July 24, 2024
The market for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to lower cholesterol is taking off with several new drugs being introduced or nearing the market, […]
July 24, 2024
High blood pressure is an established risk factor for neurodegeneration and cognitive decline. Long-standing evidence shows that treating hypertension can reduce its vascular consequences, but whether […]
July 24, 2024
The health consequences of excess visceral fat tissue are well known. But there is another type of fat accumulation in the body that increases the risk […]
July 24, 2024
TOPLINE: Researchers identified diverse gut microbial features linked to type 2 diabetes (T2D), suggesting the gut microbiome’s significant role in its pathogenesis and potential for diagnostic […]
July 24, 2024
The US Food and Drug Administration (FDA) recently approved two biosimilars to Soliris for the treatment of two rare diseases — paroxysmal nocturnal hemoglobinuria (PNH), a […]
July 24, 2024
Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself “at my ideal body weight,” with […]
July 24, 2024
TOPLINE: Topical delgocitinib, a pan-Janus kinase inhibitor, was well tolerated and reduced the severity and symptoms of disease in patients with moderate to severe chronic hand […]
July 23, 2024
Talking with Capt. Martin Shimer, the former Deputy Director of the Division of Legal and Program Support, Office of Generic Drugs, CDER. The FDA’s publication Approved […]
July 23, 2024
For Immediate Release: July 23, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, […]